Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Pharmaceutical Statistics|June 9, 2022
Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands frameworkMarian Mitroiu, Steven Teerenstra, Katrien Oude Rengerink, et al.Pharmaceutical Statistics|May 6, 2025
Applying the Principal Stratum Strategy in Equivalence Trials: A Case StudyJerome Sepin, Thomas P A Debray, Wei Wei, et al.Journal of Clinical Epidemiology|March 10, 2018
Measurement error is often neglected in medical literature: a systematic reviewTimo B Brakenhoff, Marian Mitroiu, Ruth H Keogh, et al.Pharmaceutical Statistics|March 6, 2025
Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 TrialJames Bell, Thomas Drury, Tobias Mütze, et al.Journal of Comparative Effectiveness Research|January 23, 2024
Visualizing the target estimand in comparative effectiveness studies with multiple treatmentsGabrielle Simoneau, Marian Mitroiu, Thomas Pa Debray, et al.The Lancet. Rheumatology|January 23, 2024
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trialXiaomei Leng, Piotr Leszczyński, Sławomir Jeka, et al.Arthritis Research & Therapy|September 7, 2024
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, et al.Orphanet Journal of Rare Diseases|November 14, 2018
Applicability and added value of novel methods to improve drug development in rare diseasesMarian Mitroiu, Katrien Oude Rengerink, Caridad Pontes, et al.Pageof 1